Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 48,546 Shares

by · The Cerbat Gem

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Peter Thompson sold 48,546 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06. Following the completion of the sale, the director directly owned 2,916,228 shares of the company’s stock, valued at approximately $130,092,931.08. This represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 3.9%

NASDAQ SION traded up $1.72 during trading on Monday, reaching $45.95. 670,726 shares of the company’s stock were exchanged, compared to its average volume of 474,065. Sionna Therapeutics, Inc. has a fifty-two week low of $11.77 and a fifty-two week high of $48.45. The company’s fifty day simple moving average is $38.55 and its 200-day simple moving average is $39.36.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. As a group, analysts predict that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics in the first quarter valued at approximately $667,000. Woodline Partners LP bought a new stake in Sionna Therapeutics in the first quarter worth approximately $837,000. Geode Capital Management LLC increased its stake in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $307,000. Finally, New York State Common Retirement Fund bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $118,000.

Wall Street Analyst Weigh In

SION has been the subject of a number of research analyst reports. Wedbush began coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. Guggenheim boosted their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Citigroup initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They issued an “outperform” rating on the stock. JonesTrading lifted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Monday, April 27th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Check Out Our Latest Stock Analysis on Sionna Therapeutics

Sionna Therapeutics Company Profile

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

Featured Stories